STRM.BIO

STRM.BIO

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://strm.bio

Last Round

Series Seed

2

Dec 1, 2025

Total Funding Raised

$2.26M

Momentum Score

50 /100

Company Overview

STRM.BIO is a biotechnology company that is developing a proprietary extracellular vesicle (EV) platform to deliver gene therapies directly to patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

gene therapy deliveryextracellular vesiclesin vivo gene therapynon-viral gene therapyEV deliveryexosome deliverybone marrow targetingHSC targetingrepeatable dosingrare blood diseasesdrug deliveryin vivo CAR-Tgene editing deliveryplatform licensingSmall Business Innovation ResearchSBIR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

STRM.BIO Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

STRM.BIO Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series Seed 2Dec 1, 2025
GrantOct 3, 2023
GrantJul 26, 2022
SeedMar 31, 2021

Key People

Founding team and executive leadership

Rob Hughes

CFO

Executive Team

David Raiser

Chief Operating Officer

Executive Team

STRM.BIO Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 3, 2025

    Awarded contract from ARPA-H for non-viral delivery technologies.

  • Dec 1, 2025

    Raised $8M in Series Seed 2 funding.

STRM.BIO Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

STRM.BIO Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about STRM.BIO's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range17
Year Founded2019
Last FundingDec 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.